Moneycontrol
HomeNewsBusinessMarketsSmall & Midcap Mantra: Granules India on track to test record highs

Small & Midcap Mantra: Granules India on track to test record highs

With a market cap of more than Rs 8,000 crore, the stock has been an underperformer. It hit the all-time high of Rs 437.95 in December 2020. The stock is set to test this level in 2-3 months

June 09, 2021 / 13:51 IST
Story continues below Advertisement
Granules India Ltd.

Granules India has remained flat so far in 2021, despite the smart rally seen in the pharma space. The stock has fallen more than 6 percent so far this year, compared to the rally of over 17 percent in the S&P BSE500 index, and an over 50 percent jump in the S&P BSE Healthcare index in last one year.

Granules, which has a market-capitalisation of more than Rs 8,000 crore, is on track to retest its record high level of Rs 437.95, recorded back in December 2020, in the next 2-3 months.

Story continues below Advertisement

Granules India has a presence in over 75 countries and has eight manufacturing sites. It is a vertically integrated pharma company headquartered in Hyderabad.

“Our business is bucketed into three areas - the core business which comprises our core molecules - Paracetamol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol; the emerging business that focuses on manufacturing APIs, with a focus on vertical integration; and, the CRAMS segment, which focuses on contract research and manufacturing,” the company website says.